89bio (ETNB) Stock Forecast & Price Target

Compare

899 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ETNB Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

89bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ETNB Stock 12 Month Forecast

Average Price Target

$33.50

▲(237.02%Upside)

Based on 4 Wall Street analysts offering 12 month price targets for 89bio in the last 3 months. The average price target is $33.50 with a high forecast of $55.00 and a low forecast of $12.00. The average price target represents a 237.02% change from the last price of $9.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","56":"$56","17.75":"$17.75","30.5":"$30.5","43.25":"$43.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,17.75,30.5,43.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Aug<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.13,11.735384615384616,15.340769230769231,18.946153846153848,22.551538461538463,26.15692307692308,29.762307692307694,33.36769230769231,36.973076923076924,40.57846153846154,44.183846153846154,47.78923076923077,51.394615384615385,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.13,10.081538461538463,12.033076923076923,13.984615384615385,15.936153846153847,17.88769230769231,19.839230769230767,21.79076923076923,23.74230769230769,25.693846153846152,27.645384615384614,29.596923076923076,31.548461538461538,{"y":33.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.13,8.427692307692308,8.725384615384616,9.023076923076923,9.320769230769232,9.618461538461538,9.916153846153847,10.213846153846154,10.511538461538462,10.80923076923077,11.106923076923078,11.404615384615385,11.702307692307691,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.03,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.00

Average Price Target$33.50

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason ZemanskyBank of America Securities

Bank of America Securities

$31→$30

Buy

201.81%

Upside

Reiterated

05/27/25

89bio (ETNB) Receives a Buy from Bank of America Securities

Thomas SmithLeerink Partners

Leerink Partners

$37

Buy

272.23%

Upside

Reiterated

05/01/25

89bio's Strong Position and Promising Outlook in Biopharmaceutical Sector with Pegozafermin Advancements

Brian AbrahamsRBC Capital

RBC Capital

$12

Hold

20.72%

Upside

Reiterated

05/01/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (NASDAQ: EXAS), 89bio (NASDAQ: ETNB) and Stryker (NYSE: SYK)

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$55

Buy

453.32%

Upside

Reiterated

04/29/25

Cantor Fitzgerald Initiates a Buy Rating on 89bio (ETNB)

Andrea NewkirkGoldman Sachs

Goldman Sachs

$11

Hold

10.66%

Upside

Initiated

03/14/25

89bio (ETNB) Receives a New Rating from Goldman Sachs

Geoff MeachamCiti

Citi

$25

Buy

151.51%

Upside

Initiated

03/13/25

89bio initiated with a Buy at Citi89bio initiated with a Buy at Citi

Liisa BaykoEvercore ISI

Evercore ISI

$33

Buy

231.99%

Upside

Reiterated

03/05/25

Evercore ISI Sticks to Its Buy Rating for 89bio (ETNB)We are out with our refreshed ETNB Outlook & model (inside) in which we incorporate November’s biopsy data from Boston Pharma & January data from AKRO showing reversal of fibrosis, a first for the field.

Ed ArceH.C. Wainwright

H.C. Wainwright

$29→$21

Buy

111.27%

Upside

Reiterated

02/28/25

Analysts Are Bullish on Top Healthcare Stocks: 89bio (ETNB), Lemaitre Vascular (LMAT)Our thesis on SHTG remains unchanged despite the delay. Yesterday, 89bio announced that the Phase 3 ENTRUST study of pegozafermin for severe hypertriglyceridemia (SHTG) is now scheduled to be unblinded at Week 52, vs. the previous plan at Week 26.

Andy ChenWolfe Research

Wolfe Research

$15

Buy

50.91%

Upside

Initiated

02/03/25

3 Best Stocks to Buy Now, 2/4/2025, According to Top Analysts - TipRanks.com89bio (ETNB) 89bio is a biopharmaceutical company focused on developing novel therapies for liver and metabolic diseases. Yesterday,Wolfe Research analyst Andy Chen initiated a Buy rating on the stock with a price target of $15 per share. Interestingly, six out of the seven Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 201%.

Jay OlsonOppenheimer

Oppenheimer

―

Hold

―

Reiterated

11/11/24

89bio (ETNB) Receives a Hold from Oppenheimer

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason ZemanskyBank of America Securities

Bank of America Securities

$31→$30

Buy

201.81%

Upside

Reiterated

05/27/25

89bio (ETNB) Receives a Buy from Bank of America Securities

Thomas SmithLeerink Partners

Leerink Partners

$37

Buy

272.23%

Upside

Reiterated

05/01/25

89bio's Strong Position and Promising Outlook in Biopharmaceutical Sector with Pegozafermin Advancements

Brian AbrahamsRBC Capital

RBC Capital

$12

Hold

20.72%

Upside

Reiterated

05/01/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (NASDAQ: EXAS), 89bio (NASDAQ: ETNB) and Stryker (NYSE: SYK)

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$55

Buy

453.32%

Upside

Reiterated

04/29/25

Cantor Fitzgerald Initiates a Buy Rating on 89bio (ETNB)

Andrea NewkirkGoldman Sachs

Goldman Sachs

$11

Hold

10.66%

Upside

Initiated

03/14/25

89bio (ETNB) Receives a New Rating from Goldman Sachs

Geoff MeachamCiti

Citi

$25

Buy

151.51%

Upside

Initiated

03/13/25

89bio initiated with a Buy at Citi89bio initiated with a Buy at Citi

Liisa BaykoEvercore ISI

Evercore ISI

$33

Buy

231.99%

Upside

Reiterated

03/05/25

Ed ArceH.C. Wainwright

H.C. Wainwright

$29→$21

Buy

111.27%

Upside

Reiterated

02/28/25

Andy ChenWolfe Research

Wolfe Research

$15

Buy

50.91%

Upside

Initiated

02/03/25

Jay OlsonOppenheimer

Oppenheimer

―

Hold

―

Reiterated

11/11/24

89bio (ETNB) Receives a Hold from Oppenheimer

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 89bio

1 Month

xxx

Success Rate

9/12 ratings generated profit

Average Return

+7.85%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +7.85% per trade.

3 Months

xxx

Success Rate

15/23 ratings generated profit

Average Return

+25.22%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +25.22% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

13/23 ratings generated profit

Average Return

+78.48%

reiterated a buy rating 2 months ago

Copying Thomas Smith's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of +78.48% per trade.

2 Years

xxx

Success Rate

15/23 ratings generated profit

Average Return

+33.75%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +33.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ETNB Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ETNB has received 8 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ETNB average Analyst price target in the past 3 months is 33.50.

Each month's total comprises the sum of three months' worth of ratings.

ETNB Financial Forecast

ETNB Earnings Forecast

Next quarter’s earnings estimate for ETNB is -$0.50 with a range of -$0.66 to -$0.40. The previous quarter’s EPS was -$0.49. ETNB beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year ETNB has Outperformed its overall industry.

No data currently available

ETNB Sales Forecast

Next quarter’s sales forecast for ETNB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ETNB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year ETNB has Preformed in-line its overall industry.

ETNB Stock Forecast FAQ

What is ETNB’s average 12-month price target, according to analysts?

Based on analyst ratings, 89bio’s 12-month average price target is 33.50.

What is ETNB’s upside potential, based on the analysts’ average price target?

89bio has 237.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ETNB a Buy, Sell or Hold?

89bio has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is 89bio’s price target?

The average price target for 89bio is 33.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $12.00. The average price target represents 237.02% Increase from the current price of $9.94.

What do analysts say about 89bio?

89bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of ETNB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

89bio (ETNB) Stock Forecast & Price Target

ETNB Analyst Ratings

ETNB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering 89bio

ETNB Analyst Recommendation Trends

ETNB Financial Forecast

ETNB Earnings Forecast

ETNB Sales Forecast

ETNB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts